Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 278-287

  Ferrandi, Mara ^a,b   Molinari, Isabella ^a,b   Rastaldi, Maria Pia ^c   Ferrari, Patrizia ^a,d   Bianchi, Giuseppe ^d,e   Manunta, Paolo ^b,e  

^a Prassis Sigma Tau Research Institute   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d CVie Therapeutics   (Hong Kong)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADDUCIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIHYPERTENSIVE AGENT; NEPHRIN; OUABAIN; PROTEIN SH2; PROTEIN TYROSINE KINASE; ROSTAFUROXIN; ANDROSTANE DERIVATIVE; CALMODULIN BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONGENIC STRAIN; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVATION; GENETIC VARIABILITY; GLOMERULOPATHY; MALE; MOUSE; NONHUMAN; PODOCYTE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEINURIA; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETICS; HYPERTENSION; KIDNEY; KNOCKOUT MOUSE; METABOLISM; SPRAGUE DAWLEY RAT;

ANDROSTANOLS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CALMODULIN-BINDING PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VARIATION; HYPERTENSION; KIDNEY; MALE; MICE; MICE, KNOCKOUT; OUABAIN; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84907223066     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.217133     Document Type: Article

References (39)

1. Babelova A, Jansen F, Sander K, Löhn M, Schäfer L, Fork C, Ruetten H, Plettenburg O, Stark H, and Daniel C, et al. (2013) Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease. PLoS ONE 8:e80328.
2. Bianchi G (2005) Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms. Am J Physiol Regul Integr Comp Physiol 289:R1536-R1549.
3. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, Leoni P, Torielli L, Cusi D, and Ferrandi M, et al. (1994) Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 91: 3999-4003.
4. Bignami E, Casamassima N, Frati E, Lanzani C, Corno L, Alfieri O, Gottlieb S, Simonini M, Shah KB, and Mizzi A, et al. (2013) Preoperative endogenous ouabain predicts acute kidney injury in cardiac surgery patients. Crit Care Med 41: 744-755.
5. Brandis A, Bianchi G, Reale E, Helmchen U, and Kühn K (1986) Age-dependent glomerulosclerosis and proteinuria occurring in rats of the Milan normotensive strain and not in rats of the Milan hypertensive strain. Lab Invest 55:234-243.
6. Ferrandi M, Cusi D, Molinari I, Del Vecchio L, Barlassina C, Rastaldi MP, Schena FP, Macciardi F, Marcantoni C, and Roccatello D, et al. (2010b) alpha-and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy. JMol Med (Berl) 88:203-217.
7. Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, and Ferrari P (2004) Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J Biol Chem 279:33306-33314.
8. Ferrandi M, Molinari I, Torielli L, Padoani G, Salardi S, Rastaldi MP, Ferrari P, and Bianchi G (2010a) Adducin-and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies. Sci Transl Med 2:59ra86.
9. Ferrandi M, Salardi S, Tripodi G, Barassi P, Rivera R, Manunta P, Goldshleger R, Ferrari P, Bianchi G, and Karlish SJ (1999) Evidence for an interaction between adducin and Na(+)-K(+)-ATPase: relation to genetic hypertension. Am J Physiol 277:H1338-H1349.
10. Ferrari P, Ferrandi M, Torielli L, Tripodi G, Melloni P, and Bianchi G (1999a) PST2238: A new antihypertensive compound that modulates Na, K-ATPase and antagonizes the pressor effect of OLF. Cardiovasc Drug Rev 17:39-57.
11. Ferrari P, Ferrandi M, Tripodi G, Torielli L, Padoani G, Minotti E, Melloni P, and Bianchi G (1999b) PST 2238: A new antihypertensive compound that modulates Na, K-ATPase in genetic hypertension. J Pharmacol Exp Ther 288: 1074-1083.
12. Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Florio M, Conti F, Melloni P, Vesci L, and Corsico N, et al. (1998) PST2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol Exp Ther 285:83-94.
13. Gilligan DM, Lozovatsky L, Gwynn B, Brugnara C, Mohandas N, and Peters LL (1999) Targeted disruption of the beta adducin gene (Add2) causes red blood cell spherocytosis in mice. Proc Natl Acad Sci USA 96:10717-10722.
14. Gotoh H, Okumura N, Yagi T, Okumura A, Shima T, and Nagai K (2006) Fyn-induced phosphorylation of beta-adducin at tyrosine 489 and its role in their subcellular localization. Biochem Biophys Res Commun 346:600-605.
15. Grahammer F, Schell C, and Huber TB (2013) The podocyte slit diaphragm-from a thin grey line to a complex signalling hub. Nat Rev Nephrol 9:587-598.
16. Lanzani C, Citterio L, Glorioso N, Manunta P, Tripodi G, Salvi E, Carpini SD, Ferrandi M, Messaggio E, and Staessen JA, et al. (2010) Adducin-and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Sci Transl Med 2:59ra87.
17. Levey AS and Coresh J (2012) Chronic kidney disease. Lancet 379:165-180.
18. Liu L, Doné SC, Khoshnoodi J, Bertorello A, Wartiovaara J, Berggren PO, and Tryggvason K (2001) Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome. Hum Mol Genet 10:2637-2644.
19. Liu BA, Engelmann BW, and Nash PD (2012) The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction. FEBS Lett 586: 2597-2605.
20. Manunta P, Ferrandi M, Bianchi G, and Hamlyn JM (2009) Endogenous ouabain in cardiovascular function and disease. J Hypertens 27:9-18.
21. Mathieson PW (2008) Podocyte-specific gene mutations are coming of age. J Am Soc Nephrol 19:190-191.
22. New LA, Keyvani Chahi A, and Jones N (2013) Direct regulation of nephrin tyrosine phosphorylation by Nck adaptor proteins. J Biol Chem 288:1500-1510.
23. Peltier J, Bellocq A, Perez J, Doublier S, Dubois YC, Haymann JP, Camussi G, and Baud L (2006) Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. J Am Soc Nephrol 17:3415-3423.
24. Piscione TD and Licht C (2011) Genetics of proteinuria: an overview of gene mutations associated with nonsyndromic proteinuric glomerulopathies. Adv Chronic Kidney Dis 18:273-289.
25. Pugliese F, Mene' P, and Cinotti GA (1986) Glomerular prostaglandins and thromboxane synthesis in normotensive and hypertensive rats of the Milan strain before and after development of hypertension. J Hypertens 4:S391-S393.
26. Quack I, Rump LC, Gerke P, Walther I, Vinke T, Vonend O, Grunwald T, and Sellin L (2006) beta-Arrestin2 mediates nephrin endocytosis and impairs slit diaphragm integrity. Proc Natl Acad Sci USA 103:14110-14115.
27. Quadri L, Bianchi G, Cerri A, Fedrizzi G, Ferrari P, Gobbini M, Melloni P, Sputore S, and Torri M (1997) 17 beta-(3-furyl)-5 beta-androstane-3 beta, 14 beta, 17 alpha-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem 40:1561-1564.
28. Salvati P, Ferti C, Ferrario RG, Lamberti E, Duzzi L, Bianchi G, Remuzzi G, Perico N, Benigni A, and Braidotti P, et al. (1990) Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. Kidney Int 38:447-458.
29. Simons M, Schwarz K, Kriz W, Miettinen A, Reiser J, Mundel P, and Holthöfer H (2001) Involvement of lipid rafts in nephrin phosphorylation and organization of the glomerular slit diaphragm. Am J Pathol 159:1069-1077.
30. Tian X, Kim JJ, Monkley SM, Gotoh N, Nandez R, Soda K, Inoue K, Balkin DM, Hassan H, and Son SH, et al. (2014) Podocyte-associated talin1 is critical for glo-merular filtration barrier maintenance. J Clin Invest 124:1098-1113.
31. Tripodi G, Florio M, Ferrandi M, Modica R, Zimdahl H, Hubner N, Ferrari P, and Bianchi G (2004) Effect of Add1 gene transfer on blood pressure in reciprocal congenic strains of Milan rats. Biochem Biophys Res Commun 324:562-568.
32. Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, Trusolino L, Menegon A, Ferrari P, Marchisio PC, and Bianchi G (1996) Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 97:2815-2822.
33. Turner JM, Bauer C, Abramowitz MK, Melamed ML, and Hostetter TH (2012) Treatment of chronic kidney disease. Kidney Int 81:351-362.
34. Verma R, Kovari I, Soofi A, Nihalani D, Patrie K, and Holzman LB (2006) Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest 116:1346-1359.
35. Verma R, Wharram B, Kovari I, Kunkel R, Nihalani D, Wary KK, Wiggins RC, Killen P, and Holzman LB (2003) Fyn binds to and phosphorylates the kidney slit diaphragm component Nephrin. J Biol Chem 278:20716-20723.
36. Wiggins RC (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71:1205-1214.
37. Zhang J, Lee MY, Cavalli M, Chen L, Berra-Romani R, Balke CW, Bianchi G, Ferrari P, Hamlyn JM, and Iwamoto T, et al. (2005) Sodium pump alpha2 subunits control myogenic tone and blood pressure in mice. J Physiol 569:243-256.
38. Zhao B, Tan PH, Li SS, and Pei D (2013) Systematic characterization of the specificity of the SH2 domains of cytoplasmic tyrosine kinases. J Proteomics 81: 56-69.
39. Zulian A, Linde CI, Pulina MV, Baryshnikov SG, Papparella I, Hamlyn JM, and Golovina VA (2013) Activation of c-SRC underlies the differential effects of ouabain and digoxin on Ca(21) signaling in arterial smooth muscle cells. Am J Physiol Cell Physiol 304:C324-C333.